# Radnostix Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Radnostix Inc). ## Overview RADNOSTIX INC is part of a U.S.-based nuclear medicine and isotope business that manufactures calibration and reference standards, radiochemical products, and cobalt-based source products. Its operations span medical, industrial, and research applications, with products distributed in the United States and internationally through company facilities and subsidiaries. ## Products & services • Nuclear medicine calibration and reference standards • Isotopically pure radiopharmaceuticals and radiochemicals • Sodium iodide I-131 generic drug product • Cobalt-60 bulk products and sealed sources • Recycling of expended cobalt sources • Molecular imaging QC and calibration devices - **Theranostics Products** (45%) — Radiopharmaceuticals, APIs, and radiochemicals used in medical, industrial, and research settings. - **Cobalt Products** (25%) — Bulk cobalt-60, sealed sources, capsule fabrication, and source recycling services. - **Nuclear Medicine Standards** (20%) — Calibration and reference standards and related quality-control products for imaging workflows. - **Molecular Imaging Devices** (10%) — Quality-control and calibration devices sold through RadQual and related channels. - Nuclear medicine calibration and reference standards - Isotopically pure radiopharmaceuticals and radiochemicals - Sodium iodide I-131 generic drug product - Cobalt-60 bulk products and sealed sources - Recycling of expended cobalt sources - Molecular imaging QC and calibration devices ## Customers Customers include medical device makers, radiopharmaceutical developers, hospitals and imaging centers, and research organizations that need isotope-based materials or calibration products. The company also serves industrial users that incorporate cobalt products into radiation therapy or other specialized applications. Buyers are typically seeking regulated, specialized inputs that are difficult to source domestically or require precise specifications. - **Radiopharmaceutical developers** (primary) — Buy isotopically pure radiopharmaceuticals, APIs, and radiochemicals for therapy and imaging products. - **Medical imaging and nuclear medicine users** (primary) — Buy calibration and reference standards plus QC devices to validate imaging systems and workflows. - **Radiation therapy and industrial source users** (secondary) — Buy cobalt-60 products and sealed sources for therapy, industrial, and medical applications. - **Research and clinical trial organizations** (secondary) — Buy radioisotopes for clinical trials and research programs that later feed approved products. - Radiopharmaceutical developers needing isotopes and APIs - Hospitals and imaging centers using calibration standards - Medical device makers integrating QC and reference products - Industrial users of cobalt-60 sealed sources - Research and clinical-trial customers needing labeled isotopes ## Geography The company is based in the United States and can ship products to all 50 states, while also serving international customers. Its isotope and cobalt supply chain is tied to specialized U.S. facilities and reactors, which makes domestic sourcing and logistics central to operations. The business also includes a China joint venture within its theranostics activities, adding an international operating element. - United States is the core operating and sales base - Products can be shipped to all 50 states - International sales support radiochemical and isotope demand - U.S. reactor and DOE-linked supply chain is operationally critical - China joint venture adds an overseas theranostics footprint ## Strategy The company is focused on specialized isotope and cobalt products where regulatory capability, licensing, and supply reliability create barriers to entry. It is also building a stronger role in theranostics and radiopharmaceutical supply by offering customized products and domestic alternatives to imported sources. Maintaining access to reactor-based feedstock and distributor relationships is central to preserving its market position. - **Strengthen theranostics and radiochemical offerings** (medium-term) — These products sit in a growing medical isotope market and require specialized capabilities. - **Protect isotope supply continuity** (short-term) — The business depends on just-in-time radioisotope inputs that cannot be stockpiled easily. - **Defend niche domestic manufacturing positions** (medium-term) — Domestic production and unique licensing can differentiate the company from foreign suppliers. - Expand theranostics and radiochemical product positioning - Use domestic supply capability as an alternative to imports - Leverage NRC licensing and GMP compliance as barriers to entry - Maintain access to reactor-based isotope supply - Support distributor and channel continuity ## Risks The business is exposed to supply-chain disruption because radioisotopes are sourced through specialized reactors and logistics networks that cannot be easily buffered with inventory. It also faces regulatory, distributor, and customer-concentration risk because its products are highly specialized and often tied to FDA, NRC, and DOE requirements. Broader industry risks include raw-material inflation, energy costs, and the possibility that alternative suppliers or reactor outages interrupt sales. - **Radioisotope supply interruption** [high] — The company relies on just-in-time inputs from specialized reactors and suppliers. - **Regulatory and licensing dependence** [high] — Operations depend on NRC, FDA, DOE, and transport approvals for production and shipment. - **Distributor and channel disruption** [medium] — Loss of territorial distributors could reduce access to end customers. - **Input cost inflation** [medium] — Raw materials, utilities, energy, and infrastructure costs are not fully controllable. - Just-in-time isotope supply can halt production and sales - Reactor outages or logistics failures can make shipments unusable - Regulatory approvals and licensing are essential to operations - Distributor instability could reduce revenue in some territories - Raw material and energy cost volatility can pressure margins ## Accounting Revenue recognition can be affected by shipment timing, product availability, and the specialized nature of isotope orders, which may create quarter-to-quarter volatility. The company also has judgment-heavy items such as asset-sale accounting for the fluorine products business, promissory notes from acquisitions, and potential gains or losses tied to disposal and financing transactions. Investors should also watch estimates around maintenance, licensing, and any impairment or write-down risk for specialized assets that may no longer be core to operations. - **Revenue timing for specialized product shipments** — Affects reported sales and comparability across periods - **Fluorine Products asset sale accounting** — Can materially affect income statement and balance sheet - **Promissory note and accrued interest accounting** — Affects debt balance and interest expense - **Impairment and disposal of specialized assets** — Could trigger write-downs or gains/losses on sale - Shipment timing can shift revenue between quarters - Asset sale accounting may create one-time gains or losses - Promissory notes and accrued interest affect liabilities - Specialized assets may require impairment or disposal accounting - Maintenance and licensing costs can affect segment results --- *Last updated: 2026-04-29T04:51:01.990622+00:00*